Related Experiment Videos
Tesaglitazar: a promising approach in type 2 diabetes
1Medical Information Department, Prous Science, Barcelona, Spain. journals@prous.com
Drugs of Today (Barcelona, Spain : 1998)
|April 22, 2006
Summary
Tesaglitazar, a dual PPARalpha/gamma agonist, shows promise for treating type 2 diabetes and dyslipidemia by addressing both glucose and lipid metabolism. This approach may offer combined benefits of existing therapies for insulin resistance.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology
Background:
- Type 2 diabetes management requires addressing multiple metabolic abnormalities beyond glycemic control.
- Dyslipidemia significantly increases cardiovascular disease risk in diabetic and prediabetic individuals with insulin resistance.
- Peroxisome proliferator-activated receptors (PPARs) regulate energy homeostasis and inflammation, making them therapeutic targets.
Purpose of the Study:
- To review the clinical efficacy and safety of tesaglitazar, a dual PPARalpha/gamma agonist.
- To evaluate tesaglitazar as a treatment for insulin resistance and dyslipidemia in type 2 diabetes.
- To assess tesaglitazar's potential in individuals with insulin resistance but without diabetes.
Main Methods:
- Review of available clinical data on tesaglitazar.
- Investigation of tesaglitazar's effects in phase III clinical trials.
- Analysis of efficacy and safety profiles in target patient populations.
Main Results:
- Thiazolidinediones (PPARgamma agonists) improve glycemic control and insulin sensitivity.
- Fibrates (PPARalpha agonists) improve lipid profiles and may reduce cardiovascular events.
- Tesaglitazar aims to combine the benefits of both PPARalpha and PPARgamma activation.
Conclusions:
- Dual PPAR agonists like tesaglitazar offer a theoretical advantage by targeting both glucose and lipid metabolism.
- Tesaglitazar is under investigation for its potential to treat complex metabolic issues in type 2 diabetes and insulin resistance.
- Further data from ongoing trials are crucial for establishing tesaglitazar's role in clinical practice.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...